Loading
Nanoplatforms for Cancer Theranostics / Cancer Research and Treatments · Journal article
Acs Applied Bio Materials · August 17, 2026
Early or partial results. Treat as a signal, not a conclusion.
This preclinical report describes development and characterization of a tumor-targeted nanozyme platform (CPA/OA@HA) designed to enhance chemodynamic therapy by increasing lipid peroxidation substrates and catalytic H2O2 utilization. In vitro and in vivo studies show tumor suppression and biocompatibility, but the work is mechanistic and uncontrolled, lacks efficacy comparators, and reports no human data or clinical endpoints.
Preclinical mechanistic study with in vitro and in vivo proof-of-concept. Tumor cells in vitro and tumor-bearing animals; specific cell lines, animal species, and eligibility criteria not stated in abstract. Intervention: CPA/OA@HA: mesoporous multimetallic nanozyme (CuPtAu) loaded with oleanolic acid and coated with hyaluronic acid, enabling tumor-specific CD44 targeting, intrinsic enzymatic activities (GOx, CAT, POD), and lipid metabolism modulation.
CPA/OA@HA nanozyme exhibits intrinsic glucose oxidase, catalase, and peroxidase-mimicking activities enabling self-supply of H2O2 and sustained generation of hydroxyl radicals Oleanolic acid significantly increases the proportion of polyunsaturated fatty acids (PUFAs) to provide abundant substrates for lipid peroxidation In vitro and in vivo results demonstrate remarkable tumor suppression at low doses with excellent biocompatibility
No quantified tumor suppression metrics, survival data, or toxicity outcomes provided No human safety or efficacy data; tumor model specificity and generalizability unknown
This is a foundational nanomaterial design report with no established clinical relevance. Clinicians should await controlled preclinical comparisons, toxicology data, and ultimately early-phase human trials before considering any therapeutic application.
This is an early-stage preclinical study demonstrating a novel nanozyme design in cell and animal models without clinical translation, efficacy comparators, or human data.
As stated by the source record.
This is a foundational nanomaterial design report with no established clinical relevance. Clinicians should await controlled preclinical comparisons, toxicology data, and ultimately early-phase human trials before considering any therapeutic application.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
The therapeutic efficacy of chemodynamic therapy (CDT) is severely constrained by insufficient endogenous hydrogen peroxide (H2O2), excessive glutathione (GSH)-mediated scavenging of hydroxyl radicals (·OH), and the limited abundance of lipid peroxidation (LPO) substrates due to low membrane unsaturation in tumor cells. To address these challenges, we herein develop a tumor microenvironment (TME)-responsive, multifunctional mesoporous multimetallic nanozyme (CuPtAu, CPA) loaded with the lipid metabolism modulator oleanolic acid (OA) and further coated with hyaluronic acid (HA), constructing a targeted nanoplatform (CPA/OA@HA). This system achieves tumor-specific enrichment via HA-mediated CD44 targeting and responsively releases OA within the TME, which significantly increasing the proportion of polyunsaturated fatty acids (PUFAs), thereby providing abundant substrates for LPO. Concurrently, the CPA nanozyme exhibits intrinsic glucose oxidase (GOx)-, catalase (CAT)-, and peroxidase (POD)-mimicking activities, enabling self-supply of H2O2 and O2, sustained generation of ·OH, and efficient depletion of GSH. Through a dual synergistic strategy of substrate enhancement and catalytic amplification, CPA/OA@HA potently propagates the LPO chain reaction, inducing irreversible oxidative damage to tumor cells. Both in vitro and in vivo results demonstrate remarkable tumor suppression at low doses with excellent biocompatibility. This metabolic intervention-integrated CDT strategy provides a paradigm to overcome oxidative resistance in cancer therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.